

Scott H Okuno

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3016641/publications.pdf>

Version: 2024-02-01

40
papers

2,683
citations

471509

17
h-index

315739

38
g-index

41
all docs

41
docs citations

41
times ranked

3656
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1493-1501.	10.7	921
2	Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002. <i>Journal of Clinical Oncology</i> , 2007, 25, 2755-2763.	1.6	655
3	Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 3299-3306.	1.6	132
4	Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. <i>Clinical Cancer Research</i> , 2020, 26, 1258-1266.	7.0	115
5	Combination chemotherapy for desmoid tumors. <i>Cancer</i> , 2003, 97, 1134-1135.	4.1	102
6	Phase II trial of gemcitabine in patients with advanced sarcomas (E1797). <i>Cancer</i> , 2003, 97, 1969-1973.	4.1	75
7	The enigma of desmoid tumors. <i>Current Treatment Options in Oncology</i> , 2006, 7, 438-443.	3.0	69
8	Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1110-1122.	10.7	63
9	Adjuvant chemoradiation therapy with high-dose versus weekly cisplatin for resected, locally-advanced HPV/p16-positive and negative head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2014, 50, 311-318.	1.5	53
10	Inhibition of STAT3 blocks protein synthesis and tumor metastasis in osteosarcoma cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 244.	8.6	47
11	Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma. <i>Cancer</i> , 2020, 126, 105-111.	4.1	47
12	Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016). <i>Sarcoma</i> , 2019, 2019, 1-8.	1.3	45
13	A Retrospective Analysis of the Efficacy of Immunotherapy in Metastatic Soft-Tissue Sarcomas. <i>Cancers</i> , 2020, 12, 1873.	3.7	40
14	Systemic therapy for recurrent or metastatic salivary gland malignancies. <i>Cancers of the Head & Neck</i> , 2016, 1, 11.	6.2	34
15	Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023). <i>Sarcoma</i> , 2020, 2020, 1-8.	1.3	33
16	Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib. <i>JAMA Oncology</i> , 2018, 4, 814.	7.1	26
17	A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma. <i>Cancer</i> , 2008, 112, 1772-1779.	4.1	19
18	Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. <i>Pancreatology</i> , 2020, 20, 101-109.	1.1	17

#	ARTICLE	IF	CITATIONS
19	Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung. <i>Sarcoma</i> , 2020, 2020, 1-6.	1.3	17
20	Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients—A Position Paper from the National Leiomyosarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN). <i>Cancers</i> , 2021, 13, 886.	3.7	17
21	An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma. <i>European Journal of Cancer</i> , 2021, 154, 201-208.	2.8	14
22	SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy. <i>Sarcoma</i> , 2018, 2018, 1-9.	1.3	13
23	Soft tissue sarcoma stiffness and perfusion evaluation by MRE and DCE-MRI for radiation therapy response assessment: a technical feasibility study. <i>Biomedical Physics and Engineering Express</i> , 2019, 5, 047003.	1.2	13
24	Characteristics and long-term outcomes of head and neck squamous cell carcinoma after solid organ transplantation. <i>Oral Oncology</i> , 2017, 72, 104-109.	1.5	12
25	Decreased local and systemic levels of sFRP3 protein in osteosarcoma patients. <i>Gene</i> , 2018, 674, 1-7.	2.2	12
26	Evaluating the Role of Adjuvant Radiotherapy in the Management of Sacral and Vertebral Chordoma: Results from a National Database. <i>World Neurosurgery</i> , 2019, 127, e1137-e1144.	1.3	12
27	Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas. <i>British Journal of Cancer</i> , 2021, 125, 528-533.	6.4	12
28	Frequent CTNNB1 p.S45 Mutations and Aggressive Clinical Behavior in Neuromuscular Choristoma-Associated Fibromatosis. <i>Neurosurgery</i> , 2021, 88, 804-811.	1.1	11
29	Oncolytic Measles Virotherapy and Opposition to Measles Vaccination. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1834-1839.	3.0	9
30	Clinicopathologic characteristics and survival for adult renal sarcoma: A population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 505.e15-505.e20.	1.6	7
31	Abdominopelvic inflammatory myofibroblastic tumor that metastasized to the vertebrae and liver: A case report and review of the literature. <i>Gynecologic Oncology Reports</i> , 2015, 12, 9-12.	0.6	7
32	A proof-of-concept trial of protein kinase C iota inhibition with auranofin for the paclitaxel-induced acute pain syndrome. <i>Supportive Care in Cancer</i> , 2017, 25, 833-838.	2.2	7
33	Clinicopathologic features and outcomes of gastrointestinal stromal tumors arising from the esophagus and gastroesophageal junction. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 718-727.	1.4	7
34	Pazopanib in Patients with Osteosarcoma Metastatic to the Lung: Phase 2 Study Results and the Lessons for Tumor Measurement. <i>Journal of Oncology</i> , 2022, 2022, 1-9.	1.3	6
35	Hyperbaric Oxygen as Radiation Sensitizer for Locally Advanced Squamous Cell Carcinoma of the Oropharynx: A Phase 1 Dose-Escalation Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 481-486.	0.8	5
36	A Case Series of Long-Term Surgical Outcomes of Primary Pulmonary Artery Sarcomas With Opportunities for 3D-Printed Models in Surgical Planning. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , 2021, 16, 94-100.	0.9	4

#	ARTICLE	IF	CITATIONS
37	RNA-dependent protein kinase is required for interferon- β -induced autophagy in MG63 osteosarcoma cells. <i>Gene</i> , 2021, 802, 145865.	2.2	2
38	Teaching Neurolmages: Brain and Skin Involvement in Erdheim-Chester Disease. <i>Neurology</i> , 2021, 96, e1590-e1592.	1.1	1
39	Surgical Approach and Oncologic Outcomes Following Multidisciplinary Management of Retrorectal Sarcomas. <i>Indian Journal of Surgical Oncology</i> , 2011, 2, 280-285.	0.7	0
40	Olaratumab for the treatment of advanced soft tissue sarcoma. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 883-887.	2.4	0